Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile

• Main Authors: Diego A. Díaz-Dinamarca (Author), Pablo Díaz (Author), Gisselle Barra (Author), Rodrigo Puentes (Author), Loredana Arata (Author), Jonnathan Grossolli (Author), Boris Riveros-Rodriguez (Author), Luis Ardiles (Author), Julio Santelises (Author), Valeria Vasquez-Saez (Author), Daniel F. Escobar (Author), Daniel Soto (Author), Cecilia Canales (Author), Janepsy Díaz (Author), Liliana Lamperti (Author), Daniela Castillo (Author), Mychel Urra (Author), Felipe Zuñiga (Author), Valeska Ormazabal (Author), Estefanía Nova-Lamperti (Author), Rosana Benítez (Author), Alejandra Rivera (Author), Claudia P. Cortes (Author), María Teresa Valenzuela (Author), Heriberto E. García-Escorza (Author), Abel E. Vasquez (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

IntroductionSevere acute respiratory syndrome virus 2 (SARS-CoV-2) has caused over million deaths worldwide, with more than 61,000 deaths in Chile. The Chilean government has implemented a vaccination program against SARS-CoV-2, with over 17.7 million people receiving a complete vaccination scheme....